Contact Us
Drug Search Results
More Filters [+]

Preladenant

Alternative Names: preladenant, sch 420814
Latest Update: 2023-07-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADORA2 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Preladenant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Parkinson's Disease

Phase 2: Parkinson's Disease|Brain Diseases|Movement Disorders|Dyskinesias|Psychomotor Agitation|Psychotic Disorders|Affective Disorders, Psychotic|Schizophrenia|Psychomotor Disorders|Akathisia, Drug-Induced|Parkinsonian Disorders|Dyskinesia, Drug-Induced

Phase 1: Dyskinesias|Parkinsonian Disorders|Parkinson's Disease|Oncology Solid Tumor Unspecified|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MK-3814A-062

P1

Terminated

Oncology Solid Tumor Unspecified

2017-11-24

41%
2009-015162-57

P3

Completed

Parkinson's Disease

2013-07-16

PARADYSE - Monotherapy

P3

Terminated

Parkinson's Disease

2013-07-16

PARADYSE

P3

Terminated

Parkinson's Disease

2013-07-16

Recent News Events

Date

Type

Title

07/01/2023

PubMed

 Combination immunotherapy of PEG-modified preladenant thermosensitive liposomes and PD-1 inhibitor effectively enhances the anti-tumor immune response and therapeutic effects.

12/01/2022

PubMed

 A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease: application to preladenant.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions